

MEDAREX INC  
Form 8-K  
April 06, 2006

**As filed with the Securities and Exchange Commission on April 6, 2006.**

## **SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549



**FORM 8-K**



**CURRENT REPORT**



Edgar Filing: MEDAREX INC - Form 8-K

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported)**

**April 6, 2006 (April 5, 2006)**

---

**MEDAREX, INC.**

(Exact name of registrant as specified in its charter)

**New Jersey**  
(State of other jurisdiction  
of incorporation)

**0-19312**  
(Commission File Number)

**22-2822175**  
(IRS Employer  
Identification No.)



707 State Road, Princeton, N.J. 08540-1437

Edgar Filing: MEDAREX INC - Form 8-K

(Address of Principal Executive Offices)

**Registrant's telephone number, including area code: (609) 430-2880**

**Not Applicable**

Edgar Filing: MEDAREX INC - Form 8-K

(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
  - o Soliciting material pursuant to Rule 14A-12 under the Exchange Act (17 CFR 240.14a-12)
  - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR.14d-2(b))
  - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**MEDAREX, INC.**

**TABLE OF CONTENTS**

**FOR**

**CURRENT REPORT ON FORM 8-K**

Item 8.01

Other Events

Item 9.01

Financial Statements and Exhibits.

Signature

**Item 8.01. Other Events.**

**EXPLANATORY NOTE**

On April 5, 2006, Medarex, Inc. filed a Form 8-K with the Securities and Exchange Commission via the EDGAR filing system that included an Exhibit 99.1 attached thereto and incorporated by reference therein. Such exhibit inadvertently contained a reference to the information set forth therein being filed pursuant to Rule 433 of the Securities Act of 1933, as amended. Such information was not intended to be filed pursuant to such rule, but instead was intended to be filed only under the rules and regulations of the Securities and Exchange Commission relating to filings pursuant to Form 8-K. A revised version of such exhibit with the reference to the filing under Rule 433 deleted is attached hereto as Exhibit 99.1 and is incorporated herein by reference and filed herewith. No other changes have been made to such exhibit by this filing other than changes reflecting non-material typographical errors.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

**Exhibit  
Number**

99.1 Medarex, Inc. Information relating to certain clinical trials of ipilimumab (also known as MDX-010) dated April 5, 2006.



**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MEDAREX, INC.  
Registrant

Date: April 6, 2006

By: */s/ W. Bradford Middlekauff*  
W. Bradford Middlekauff  
*Senior Vice President, General Counsel and Secretary*

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Description</b>	<b>Page Number</b>
99.1	Medarex, Inc. information relating to certain clinical trials of ipilimumab (also known as MDX-010) dated April 5, 2006.	